| 9.12 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.72 | 1-year : | 10.77 |
| Resists | First : | 9.18 | Second : | 9.22 |
| Pivot price | 9.11 | |||
| Supports | First : | 9.11 | Second : | 7.58 |
| MAs | MA(5) : | 9.11 | MA(20) : | 9.11 |
| MA(100) : | 8.38  |
MA(250) : | 8.53  |
|
| MACD | MACD : | 0 |
Signal : | 0.01 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 61.02 | |||
| 52-week | High : | 13.22 | Low : | 4.3 |
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Fri, 12 Apr 2024
Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies UK
Fri, 19 Nov 2021
Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid ... - GlobeNewswire
Mon, 11 Oct 2021
Pacira BioSciences (PCRX) Confirms Deal to Acquire Flexion Therapeutics (FLXN) - StreetInsider.com
Mon, 11 Oct 2021
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain ... - GlobeNewswire
Wed, 04 Aug 2021
Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates - Yahoo! Voices
Thu, 12 Mar 2020
Flexion Therapeutics (FLXN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Movies UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 50 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 93.2 (%) |
| Shares Short | 1,870 (K) |
| Shares Short P.Month | 5,670 (K) |
| EPS | -1.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.13 |
| Profit Margin | -92.52 % |
| Operating Margin | -71.24 % |
| Return on Assets (ttm) | -18.99 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 82.4 % |
| Gross Profit (p.s.) | 1.32 |
| Sales Per Share | 2.04 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -59 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -4.78 |
| PEG Ratio | 0 |
| Price to Book value | -8.15 |
| Price to Sales | 4.46 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|